Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
r-AAV-TGFβRD
- Development stage
- Preclinical
- Lead developer
- LSU Health Sciences Center New Orleans
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
r-AAV-TGFβRD is a recombinant adeno-associated virus (r-AAV) vector encoding a soluble transforming growth factor-beta receptor decoy (TGFβRD). It is designed to inhibit TGF-β signaling intratumorally, thereby overcoming the immunosuppressive tumor microenvironment (TME) in triple-negative breast cancer (TNBC) without the systemic toxicity associated with other TGF-β inhibitors. The construct features a C1QTNF3-derived collagen domain (CD) to facilitate the trimerization and stabilization of the secreted fusion proteins. Preclinical studies demonstrate that intratumoral administration of r-AAV-TGFβRD reduces tumor growth, increases tumor-infiltrating lymphocytes (such as CD3+ and CD8+ T cells), and synergizes with chemotherapy (paclitaxel) to enhance anti-tumor efficacy.
- Other names
- AAV/TGFβRDrecombinant adeno-associated virus encoding a soluble TGF-beta receptor decoyrecombinant adeno-associated virus encoding a soluble TGF-β receptor decoy
02
Targets
TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on r-AAV-TGFβRD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on r-AAV-TGFβRD.